ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION

• Main Authors: M. V. Leonova (Author), M. A. Demidova (Author), A. V. Tarasov (Author), Y. V. Belousov (Author)
• Format: Book
• Published: Столичная издательская компания, 2015-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p><strong>Aim.</strong> To estimate antihypertensive, organ protective and metabolic efficiency of angiotensin converting enzyme (ACE) inhibitor spirapril in patients with arterial hypertension (AH).</p><p><strong>Material and methods.</strong> 30 patients with AH of I-II grade with different cardiovascular risk were included into the study. Spirapril was prescribed in the dose of 3 mg once daily. If necessary, daily dose could be increased to 6 mg after two weeks, and after next 4 weeks hydrochlorothiazide in daily dose 12,5-25 mg could be added. Treatment lasted 16 weeks. Before and after 16-week treatment ambulatory blood pressure monitoring (ABPM) was carried out. At the same time vasodilatation tests for reactive hyperemia and nitroglycerin were held, microalbuminuria and β2-microglobulinuria levels were defined, figures of lipid and glucose metabolism were studied, questionnaires for quality of life were filled in.</p><p><strong>Results.</strong> 27 patients with AH finished the study according to protocol. Treatment with spirapril within 16 weeks caused normalization of blood pressure in 60% of patients, decreased levels of microalbuminuria (p<0,05) and β2-microglobulinuria (p<0,05), recovered significantly disrupted endothelial function according to the results of vasodilatation tests (p<0,01), improved patients quality of life (p<0,05). Spirapril didn't change lipid and glucose metabolism, regardless that in 1/3 of cases it was used in combination with hydrochlorothiazide.</p><p><strong>Conclusion.</strong> Spirapril is a highly efficient antihypertensive drug with organ protective effect and metabolic neutrality. According to the revealed qualities it can be recommended to patients with AH with high cardiovascular risk.</p>

Item Description

1819-6446
2225-3653
10.1234/1819-6446-2005-2-4-8